NYSE - Delayed Quote • USD
Elanco Animal Health Incorporated (ELAN)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 4:06 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 13 | 12 |
| Avg. Estimate | 0.26 | 0.24 | 0.92 | 1.06 |
| Low Estimate | 0.25 | 0.2 | 0.88 | 0.96 |
| High Estimate | 0.27 | 0.27 | 0.97 | 1.14 |
| Year Ago EPS | 0.45 | 0.18 | 0.89 | 0.92 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 12 | 12 |
| Avg. Estimate | 1.17B | 1.15B | 4.5B | 4.67B |
| Low Estimate | 1.17B | 1.09B | 4.46B | 4.54B |
| High Estimate | 1.18B | 1.18B | 4.54B | 4.76B |
| Year Ago Sales | 1.26B | 1.06B | 4.42B | 4.5B |
| Sales Growth (year/est) | -6.50% | 9.10% | 1.80% | 3.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.29 | 0.05 | 0.12 | 0.11 |
| EPS Actual | 0.45 | 0.18 | 0.18 | 0.08 |
| Difference | 0.16 | 0.13 | 0.06 | -0.03 |
| Surprise % | 55.20% | 260.00% | 50.00% | -27.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.26 | 0.24 | 0.92 | 1.06 |
| 7 Days Ago | 0.26 | 0.24 | 0.92 | 1.06 |
| 30 Days Ago | 0.26 | 0.24 | 0.92 | 1.06 |
| 60 Days Ago | 0.3 | 0.25 | 0.89 | 0.99 |
| 90 Days Ago | 0.3 | 0.25 | 0.89 | 1.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ELAN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -42.20% | -- | -- | 1.50% |
| Next Qtr. | 33.30% | -- | -- | 11.40% |
| Current Year | 3.40% | -- | -- | 5.20% |
| Next Year | 15.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 8.87% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -3.31% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Piper Sandler: Neutral to Neutral | 3/12/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 2/27/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 2/27/2024 |
| Maintains | Barclays: Overweight to Overweight | 2/27/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 1/17/2024 |
| Upgrade | Stifel: Hold to Buy | 1/5/2024 |
Related Tickers
EOLS Evolus, Inc.
11.50
-1.71%
DCPH Deciphera Pharmaceuticals, Inc.
14.62
-0.34%
ZTS Zoetis Inc.
150.88
+0.88%
DVAX Dynavax Technologies Corporation
11.42
-2.89%
ESPR Esperion Therapeutics, Inc.
2.1300
+1.91%
VTRS Viatris Inc.
11.55
+1.67%
PETQ PetIQ, Inc.
16.53
-0.42%
AVDL Avadel Pharmaceuticals plc
17.66
-2.38%
BHC Bausch Health Companies Inc.
8.56
+0.35%
TEVA Teva Pharmaceutical Industries Limited
13.01
0.00%